Ligase BioPartners is a life sciences venture builder fund dedicated to advancing breakthrough oncology innovations. We partner with exceptional scientists developing therapeutics, diagnostics, and platforms that meaningfully improve patient lives.
The Ligase BioPartners team brings decades of expertise in life sciences venture capital, strategic guidance, and operational support needed to accelerate development of early stage innovation.
Cheryl is the former Investment Director at M Ventures, where she led Seed and Series A investments in Calypso Biotech, Rewind Therapeutics, Outrun Therapeutics, Multitude Therapeutics, ImmuneBridge, and several other emerging life science companies.
Her track record includes successful exits such as Calypso (acquired by Novartis) and VAXXIM (acquired by NEC/BCME). Cheryl holds a Ph.D. in Oncology from the University of Amsterdam and serves on the Board of Directors of Laigo Bio.
Shobhit is the former Managing Director of the Oncode Oncology Bridge Fund I, where he built and financed early-stage therapeutic and platform companies emerging from the Oncode Institute. Previously, he was an Investment Manager at Amsterdam Academic Ventures, focusing on company creation and early financings across life sciences and technology.
Shobhit holds a Ph.D. in Immunology from the University of Amsterdam and serves on the Board of Directors of sCellgen, 51x Therapeutics, Genase Therapeutics, and Simmunext Biotherapeutics.
The companies we create are designed to deliver real clinical impact, grounded in rigorous science and focused on unmet patient needs.
Our portfolio highlights ventures emerging from the Oncode Institute and other leading Dutch research centers that are now advancing innovative approaches across oncology therapeutics, diagnostics, and enabling technologies.
Targeting novel biology in oncology with a focus on translating academic discovery into first-in-class small molecule therapeutics.
Developing next-generation immuno-oncology and targeted degradation approaches with the potential to overcome resistance and broaden patient benefit.
Enabling high-resolution single-cell analysis to support discovery and development of precision oncology therapeutics.
Focused on developing differentiated therapies aimed at hard-to-treat solid tumors.
Engineering cell therapies designed to modulate the tumor microenvironment and enhance durable responses.
Developing ultrasensitive liquid biopsy solutions for the detection and monitoring of cancer through circulating tumor DNA.
Therapeutic programs aimed at addressing key drivers of tumor progression and resistance.
Building a pipeline of precision therapies based on deep insights into cancer genetics and biology.
Developing immuno-oncology therapies designed to modulate immune responses and enhance anti-tumor activity.
Pursuing innovative therapeutic approaches to deliver meaningful benefit in difficult-to-treat cancers.
Early-stage stealth oncology company advancing a novel approach to treating cancer. Further details to be disclosed at a later stage.
To share an opportunity, explore collaboration, or learn more about Ligase BioPartners, please reach out using the form below.